Lineage Cell Therapeutics reported second quarter 2026 financial results, posting net income of $1.5 million ($0.01 basic EPS), a significant turnaround from the $30.5 million loss in the prior year period driven by non-cash warrant liability remeasurement gains and the absence of a previous impairment charge. Total revenues declined to $1.1 million from $2.8 million due to lower collaboration revenue recognition under the Roche Agreement, while operating expenses fell to $10.0 million as R&D costs rose to $4.8 million and G&A increased to $5.2 million. The company holds $50.8 million in cash and marketable securities, sufficient to fund operations through Q3 2028. Clinically, the firm highlighted sustained positive Phase 1/2a data for RG6501 (OpRegen) at three years, advanced its wholly-owned COR1 corneal therapy program into animal testing, and initiated enrollment in the OPC1 spinal cord injury DOSED study. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic cell therapies for serious medical conditions.

Lineage Cell Therapeutics, Inc. withdrew its application for a Clinical Trial (CLIN2) award from the California Institute for Regenerative Medicine (CIRM) on June 9, 2026, following feedback on the application. The company stated the withdrawal will not affect the ongoing DOSED clinical study evaluating the safety and utility of a spinal cord delivery device for administering OPC1 to treat spinal cord injuries. Additionally, the company held its annual meeting of shareholders on June 10, 2026, where seven directors were elected, the appointment of Baker Tilly US, LLP as independent auditor was ratified, and advisory executive compensation was approved. Lineage Cell Therapeutics is a biotechnology company focused on developing cell therapies for spinal cord injuries.